Status:
COMPLETED
Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
Lead Sponsor:
Novartis
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE4
Brief Summary
This is a prospective, multicenter, open-label study. Following screening and baseline assessments, eligible patients will be switched to rivastigmine and will enter the 16 week run-in rivastigmine tr...
Eligibility Criteria
Inclusion
- Outpatients who have probable Alzheimer's disease according to the DSMIV criteria
- Patients treated with donepezil (5-10 mg ) or galantamine (16- 24 mg) for at least 6 months
- Patients, in the investigator's clinical judgment, not stabilized on treatment with donepezil or galantamine
Exclusion
- Patients with evidence of severe or unstable physical illness, i.e., acute and severe asthmatic conditions, severe or unstable cardiovascular disorders, active peptic ulcer disease, hypersensitivity to cholinesterase inhibitors or memantine, clinically significant laboratory abnormalities or any patient with a medical condition which would prohibit them from completing the clinical trial
Key Trial Info
Start Date :
November 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2005
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT00234637
Start Date
November 1 2003
End Date
June 1 2005
Last Update
November 17 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Département de Gérontologie Clinique
Limoges, Cedex, France, 87042